Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Orthofix, Stryker Preparing To Capitalize On Growing Bone Graft Market

This article was originally published in The Gray Sheet

Executive Summary

Orthofix is looking to benefit from a growing bone graft market as development and marketing partner Stryker expands indications for Orthofix' BoneSource bone substitute material.

You may also be interested in...



Orthofix

Damages from company's successful breach of contract suit against Biomet's EBI subsidiary remain at $64 mil. following the U.S. Supreme Court's denial of Orthofix' petition to review a Third Circuit U.S. Court of Appeals decision that reduced punitive damages from $50 mil. to $1 mil. (1"The Gray Sheet" July 5, In Brief), firm announces Jan. 10. The $64 mil. total includes approximately $49 mil. in compensatory damages and $14.3 mil. in pre- and post-judgement interest. Orthofix expects to net approximately $40 mil. after legal fees and previously announced expenses

Orthofix

Thirteen-center U.S. safety and efficacy clinical trial of the firm's Cervical-Stim non-invasive bone growth stimulator is set to begin following investigational device exemption approval from FDA Sept. 27. The study will evaluate the device for increasing cervical fusion rates for high-risk patients who have a failure rate of up to 50% either from smoking or multi-level fusions, the firm says

Stryker

Completes acquisition of Pfizer's Howmedica orthopedic division for $1.65 bil. in cash, the firms report Dec. 4. The deal was first announced in August ("The Gray Sheet" Aug. 17, p. 3)

Related Content

UsernamePublicRestriction

Register

LL010986

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel